Zeprumetostat
Sponsors
Sun Yat-sen University, The First Affiliated Hospital of Soochow University, Rong Tao, Institute of Hematology & Blood Diseases Hospital, China, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions
Bladder CancerBladder Urothelial CarcinomaExtranodal NK/T-cell LymphomaFollicular LymphomaGastric Cancer/Gastroesophageal Junction AdenocarcinomaLarge Granular Lymphocyte LeukemiaMature T-cell and NK-cell LymphomaNK/T-cell Lymphoma
Phase 1
EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas
Not yet recruitingNCT07339527
Start: 2026-01-01End: 2030-01-01Target: 60Updated: 2026-01-14
Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
RecruitingNCT07502768
Start: 2026-04-30End: 2028-12-30Target: 107Updated: 2026-06-18
A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia
Not yet recruitingNCT07692529
Start: 2026-08-30End: 2028-02-26Target: 10Updated: 2026-09-21
Phase 2
Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL
RecruitingNCT07372352
Start: 2026-01-15End: 2029-07-15Target: 26Updated: 2026-01-28
Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
RecruitingNCT07555470
Start: 2026-04-10End: 2029-12-31Target: 80Updated: 2026-06-09
Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer
RecruitingNCT07717242
Start: 2026-07-01End: 2029-01-31Target: 80Updated: 2026-07-21
Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemotherapy as First-Line Treatment for Metastatic GC/GEJC
Not yet recruitingNCT07874425
Start: 2026-10-01End: 2028-12-01Target: 55Updated: 2026-10-14